Abbott receives FDA approval for its TactiFlex™ Duo Ablation Catheter to treat people with abnormal heart rhythms

{
  "signal_id": "eef9d590-6e12-0e8a-008a-8e0216d16e36",
  "signal_type": "news",
  "signal_subtype": "launches",
  "detected_at": "2026-09-08T12:00:00+00:00",
  "company": {
    "name": "Abbott",
    "domain": "abbott.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/abbott-receives-fda-approval-for-its-tactiflex-duo-ablation-catheter-to-treat-people-with-abnormal-heart-rhythms-302871643.html",
    "title": "Abbott receives FDA approval for its TactiFlex™ Duo Ablation Catheter to treat people with abnormal heart rhythms - PR Newswire",
    "excerpt": "ABBOTT PARK, Ill. , Sept. 8, 2026 /PRNewswire/ -- Abbott, the global healthcare leader, announced today it has received U.S. Food and Drug Administration (FDA) approval for the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ to treat patients with challenging cases of atrial fibrillation (AFib). The U.S. approval of this dual-energy catheter, the latest generation of Abbott's cardiac ablation technology, marks a significant milestone in Abbott's commitment to advancing therapies that help physicians treat complex heart rhythms with greater precision and flexibility. Abbott will soon begin cases with broader commercial adoption across the country in the coming weeks. Why cardiac ablation matters for people with AFib For the 10.5 million people in the U.S. who live with a heart that beats too fast, too slow or in an irregular way, treatment is critical as AFib increases the risk of serious complications, including stroke. 1 , 2 While many people are treated with medications, others require cardiac ablation, a minimally invasive procedure that targets the tissue responsible for abnormal electrical signals in the heart. TactiFlex Duo is Abbott's latest ablation catheter designed to give physicians more flexibility when treating AFib. The technology allows physicians to use pulsed field ablation (PFA), radiofrequency (RF) energy, or a combination of both during a procedure...",
    "product": "TactiFlex Duo Ablation Catheter, Sensor Enabled",
    "summary": "Abbott received U.S. Food and Drug Administration (FDA) approval for its TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, designed to treat patients with atrial fibrillation (AFib).",
    "location": "United States",
    "planning": false,
    "image_url": "https://mma.prnewswire.com/media/2761216/Abbott_New_Logo.jpg?p=facebook",
    "confidence": 1,
    "product_data": {
      "name": "TactiFlex Duo Ablation Catheter, Sensor Enabled",
      "full_text": "TactiFlex™ Duo Ablation Catheter, Sensor Enabled™",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-09-08T12:00:00Z",
    "location_data": [
      {
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-09-08",
    "article_sentence": "Abbott, the global healthcare leader, announced today it has received U.S. Food and Drug Administration (FDA) approval for the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ to treat patients with challenging cases of atrial fibrillation (AFib).",
    "related_company_name": "U.S. Food and Drug Administration",
    "related_company_domain": "fda.gov"
  }
}

curl https://signals.autobound.ai/v1/signals/eef9d590-6e12-0e8a-008a-8e0216d16e36 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"abbott.com","limit":20}'